Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
- Conditions
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 219
- Registration Number
- NCT00614471
Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 294
- Registration Number
- NCT00597259
- Locations
- 🇨🇳
National Taiwan University Hospital Department of Internal medicine, Taipei, Taiwan
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 64
- Registration Number
- NCT00423891
- Locations
- 🇺🇸
Connecticut Children'S Medical Center, Hartford, Connecticut, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Mount Sinai School Of Medicine, New York, New York, United States
Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT00412529
- Locations
- 🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of
🇰🇷Gachon Univ. Gil Medical Center Hospital, Incheon, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 669
- Registration Number
- NCT00410072
- Locations
- 🇺🇸
University Of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Sergio E. Rojter, Los Angeles, California, United States
🇺🇸Tuan Nguyen, Md, San Diego, California, United States
Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
- Conditions
- Interventions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 629
- Registration Number
- NCT00410202
- Locations
- 🇺🇸
University Of Connecticut Health Center, Farmington, Connecticut, United States
🇹🇷Local Institution, Trabzon, Turkey
Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 109
- Registration Number
- NCT00395018
- Locations
- 🇺🇸
University Of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Tulane University Hospital & Clinic, New Orleans, Louisiana, United States
🇺🇸Baylor College Of Medicine, Houston, Texas, United States
A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection
- Conditions
- Interventions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 122
- Registration Number
- NCT00393484
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12522
- Registration Number
- NCT00388674
- Locations
- 🇺🇸
Office Of Sing Chan Md, Flushing, New York, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Scti Research Foundation, Coronado, California, United States
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection
- First Posted Date
- 2006-09-01
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 131
- Registration Number
- NCT00371150
- Locations
- 🇺🇸
Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
🇺🇸University Of Arizona, Tucson, Arizona, United States
🇺🇸Empire International Research, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.